{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:49:32Z","timestamp":1794005372298,"version":"4.8.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chongqing Technology Innovation and Application Development Special Key Project","award":["No. CSTB2023TIAD-STX0003"],"award-info":[{"award-number":["No. CSTB2023TIAD-STX0003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-024-02210-9","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T09:51:34Z","timestamp":1736589094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["AXL: shapers of tumor progression and immunosuppressive microenvironments"],"prefix":"10.1186","volume":"24","author":[{"given":"Yihui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyao","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"issue":"3","key":"2210_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"3","key":"2210_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2023.01.010","volume":"41","author":"O Elhanani","year":"2023","unstructured":"Elhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023;41(3):404\u201320.","journal-title":"Cancer Cell"},{"issue":"6","key":"2210_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845\u201365.","journal-title":"Cancer Cell"},{"issue":"1","key":"2210_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341.","journal-title":"Immunity"},{"issue":"7","key":"2210_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s43018-021-00221-9","volume":"2","author":"L Haas","year":"2021","unstructured":"Haas L, Elewaut A, Gerard CL, Umkehrer C, Leiendecker L, Pedersen M, et al. Acquired resistance to anti-mapk targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nat Cancer. 2021;2(7):693\u2013708.","journal-title":"Nat Cancer"},{"issue":"1","key":"2210_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pccm.2022.11.001","volume":"1","author":"L Wang","year":"2023","unstructured":"Wang L, Jia Q, Chu Q, Zhu B. Targeting tumor microenvironment for non-small cell lung cancer immunotherapy. Chin Med J Pulm Crit Care Med. 2023;1(1):18\u201329.","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"2210_CR7","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"2210_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O\u2019Dea A, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: neopact phase 2 clinical trial. Jama Oncol. 2024;10(2):227\u201335.","journal-title":"Jama Oncol"},{"issue":"9","key":"2210_CR9","doi-asserted-by":"publisher","first-page":"e005320","DOI":"10.1136\/jitc-2022-005320","volume":"10","author":"M Casarrubios","year":"2022","unstructured":"Casarrubios M, Provencio M, Nadal E, Insa A, Del RGM, Lazaro-Quintela M, et al. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable nsclc patients treated with neoadjuvant chemoimmunotherapy. J Immunother Cancer. 2022;10(9):e005320.","journal-title":"J Immunother Cancer."},{"issue":"4","key":"2210_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","volume":"3","author":"H Yao","year":"2019","unstructured":"Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, et al. Inhibiting pd-l1 palmitoylation enhances t-cell immune responses against tumours. Nat Biomed Eng. 2019;3(4):306\u201317.","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"2210_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the pd-l1 checkpoint. Immunity. 2018;48(3):434\u201352.","journal-title":"Immunity"},{"issue":"7","key":"2210_CR12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jtho.2023.03.012","volume":"18","author":"D Sun","year":"2023","unstructured":"Sun D, Liu J, Zhou H, Shi M, Sun J, Zhao S, et al. Classification of tumor immune microenvironment according to programmed death-ligand 1 expression and immune infiltration predicts response to immunotherapy plus chemotherapy in advanced patients with nsclc. J Thorac Oncol. 2023;18(7):869\u201381.","journal-title":"J Thorac Oncol"},{"key":"2210_CR13","doi-asserted-by":"publisher","first-page":"101040","DOI":"10.1016\/j.drup.2023.101040","volume":"73","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Song B, Wei H, Liu Y, Zhang W, Yang Y, et al. Ndrg1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting atg9a-dependent degradation of mhc-1. Drug Resist Updat. 2024;73:101040.","journal-title":"Drug Resist Updat"},{"issue":"11","key":"2210_CR14","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1136\/gutjnl-2018-317624","volume":"68","author":"RC Turkington","year":"2019","unstructured":"Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, et al. Immune activation by dna damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. Gut. 2019;68(11):1918\u201327.","journal-title":"Gut"},{"issue":"1","key":"2210_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu C, Wei Y, Wei X. Axl receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18(1):153.","journal-title":"Mol Cancer"},{"issue":"1","key":"2210_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pccm.2022.10.001","volume":"1","author":"S Sun","year":"2023","unstructured":"Sun S. Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation egfr inhibitors. Chin Med J Pulm Crit Care Med. 2023;1(1):3\u201310.","journal-title":"Chin Med J Pulm Crit Care Med"},{"issue":"1","key":"2210_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","volume":"42","author":"Y Tang","year":"2023","unstructured":"Tang Y, Zang H, Wen Q, Fan S. Axl in cancer: a modulator of drug resistance and therapeutic target. J Exp Clin Cancer Res. 2023;42(1):148.","journal-title":"J Exp Clin Cancer Res"},{"key":"2210_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-immunol-032414-112103","volume":"33","author":"CV Rothlin","year":"2015","unstructured":"Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S. Tam receptor signaling in immune homeostasis. Annu Rev Immunol. 2015;33:355\u201391.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"2210_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41571-023-00813-7","volume":"20","author":"D DeRyckere","year":"2023","unstructured":"DeRyckere D, Huelse JM, Earp HS, Graham DK. Tam family kinases as therapeutic targets at the interface of cancer and immunity. Nat Rev Clin Oncol. 2023;20(11):755\u201379.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2210_CR20","doi-asserted-by":"publisher","first-page":"e009165","DOI":"10.1136\/jitc-2024-009165","volume":"12","author":"C Lu","year":"2024","unstructured":"Lu C, Gao Z, Wu D, Zheng J, Hu C, Huang D, et al. Understanding the dynamics of tki-induced changes in the tumor immune microenvironment for improved therapeutic effect. J Immunother Cancer. 2024;12(6):e009165.","journal-title":"J Immunother Cancer."},{"issue":"7","key":"2210_CR21","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.7150\/thno.52435","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Gao A, Zhang F, Yang Z, Wang S, Fang Y, et al. Ilt4 inhibition prevents tam- and dysfunctional t cell-mediated immunosuppression and enhances the efficacy of anti-pd-l1 therapy in nsclc with egfr activation. Theranostics. 2021;11(7):3392\u2013416.","journal-title":"Theranostics"},{"key":"2210_CR22","doi-asserted-by":"publisher","first-page":"216205","DOI":"10.1016\/j.canlet.2023.216205","volume":"564","author":"J Lu","year":"2023","unstructured":"Lu J, Li J, Lin Z, Li H, Lou L, Ding W, et al. Reprogramming of tams via the stat3\/cd47-sirpalpha axis promotes acquired resistance to egfr-tkis in lung cancer. Cancer Lett. 2023;564:216205.","journal-title":"Cancer Lett"},{"issue":"9","key":"2210_CR23","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1158\/2326-6066.CIR-21-0751","volume":"10","author":"K Nishii","year":"2022","unstructured":"Nishii K, Ohashi K, Tomida S, Nakasuka T, Hirabae A, Okawa S, et al. Cd8+ t-cell responses are boosted by dual pd-1\/vegfr2 blockade after egfr inhibition in egfr-mutant lung cancer. Cancer Immunol Res. 2022;10(9):1111\u201326.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"2210_CR24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrc3847","volume":"14","author":"DK Graham","year":"2014","unstructured":"Graham DK, DeRyckere D, Davies KD, Earp HS. The tam family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14(12):769\u201385.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2210_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0955-0674(03)00107-8","volume":"15","author":"M Yamagata","year":"2003","unstructured":"Yamagata M, Sanes JR, Weiner JA. Synaptic adhesion molecules. Curr Opin Cell Biol. 2003;15(5):621\u201332.","journal-title":"Curr Opin Cell Biol"},{"key":"2210_CR26","doi-asserted-by":"publisher","first-page":"43908","DOI":"10.1038\/srep43908","volume":"7","author":"SG Kimani","year":"2017","unstructured":"Kimani SG, Kumar S, Bansal N, Singh K, Kholodovych V, Comollo T, et al. Small molecule inhibitors block gas6-inducible tam activation and tumorigenicity. Sci Rep. 2017;7:43908.","journal-title":"Sci Rep"},{"issue":"1","key":"2210_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/sj.emboj.7600912","volume":"25","author":"T Sasaki","year":"2006","unstructured":"Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, Ullrich A, et al. Structural basis for gas6-axl signalling. Embo J. 2006;25(1):80\u20137.","journal-title":"Embo J"},{"issue":"11","key":"2210_CR28","doi-asserted-by":"publisher","first-page":"874","DOI":"10.18632\/oncotarget.360","volume":"2","author":"M Dufies","year":"2011","unstructured":"Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, et al. Mechanisms of axl overexpression and function in imatinib-resistant chronic myeloid leukemia cells. Oncotarget. 2011;2(11):874\u201385.","journal-title":"Oncotarget"},{"issue":"5","key":"2210_CR29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/mi.2014.129","volume":"8","author":"T Fujimori","year":"2015","unstructured":"Fujimori T, Grabiec AM, Kaur M, Bell TJ, Fujino N, Cook PC, et al. The axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung. Mucosal Immunol. 2015;8(5):1021\u201330.","journal-title":"Mucosal Immunol"},{"issue":"2","key":"2210_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.canlet.2008.04.017","volume":"268","author":"CC Hong","year":"2008","unstructured":"Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, et al. Receptor tyrosine kinase axl is induced by chemotherapy drugs and overexpression of axl confers drug resistance in acute myeloid leukemia. Cancer Lett. 2008;268(2):314\u201324.","journal-title":"Cancer Lett"},{"issue":"4","key":"2210_CR31","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","volume":"70","author":"SJ Holland","year":"2010","unstructured":"Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective small molecule inhibitor of axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010;70(4):1544\u201354.","journal-title":"Cancer Res"},{"issue":"3","key":"2210_CR32","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1073\/pnas.0909333107","volume":"107","author":"C Gjerdrum","year":"2010","unstructured":"Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010;107(3):1124\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2210_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-3-319-39406-0_5","volume":"930","author":"I Dransfield","year":"2016","unstructured":"Dransfield I, Farnworth S. Axl and mer receptor tyrosine kinases: distinct and nonoverlapping roles in inflammation and cancer? Adv Exp Med Biol. 2016;930:113\u201332.","journal-title":"Adv Exp Med Biol"},{"issue":"15","key":"2210_CR34","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2174\/0929867323666160405112954","volume":"23","author":"C Corno","year":"2016","unstructured":"Corno C, Gatti L, Lanzi C, Zaffaroni N, Colombo D, Perego P. Role of the receptor tyrosine kinase axl and its targeting in cancer cells. Curr Med Chem. 2016;23(15):1496\u2013512.","journal-title":"Curr Med Chem"},{"issue":"1","key":"2210_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/1541-7786.MCR-16-0157","volume":"15","author":"K Balaji","year":"2017","unstructured":"Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, et al. Axl inhibition suppresses the dna damage response and sensitizes cells to parp inhibition in multiple cancers. Mol Cancer Res. 2017;15(1):45\u201358.","journal-title":"Mol Cancer Res"},{"issue":"31","key":"2210_CR36","doi-asserted-by":"publisher","first-page":"50403","DOI":"10.18632\/oncotarget.18468","volume":"8","author":"J Onken","year":"2017","unstructured":"Onken J, Vajkoczy P, Torka R, Hempt C, Patsouris V, Heppner FL, et al. Phospho-axl is widely expressed in glioblastoma and associated with significant shorter overall survival. Oncotarget. 2017;8(31):50403\u201314.","journal-title":"Oncotarget"},{"issue":"8","key":"2210_CR37","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/jcp.25745","volume":"232","author":"A Di Benedetto","year":"2017","unstructured":"Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, et al. Association between axl, hippo transducers, and survival outcomes in male breast cancer. J Cell Physiol. 2017;232(8):2246\u201352.","journal-title":"J Cell Physiol"},{"issue":"7913","key":"2210_CR38","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-022-04774-2","volume":"606","author":"ME Fane","year":"2022","unstructured":"Fane ME, Chhabra Y, Alicea GM, Maranto DA, Douglass SM, Webster MR, et al. Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature. 2022;606(7913):396\u2013405.","journal-title":"Nature"},{"issue":"11","key":"2210_CR39","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","volume":"12","author":"A Noronha","year":"2022","unstructured":"Noronha A, Belugali NN, Lee JS, Zhitomirsky B, Oren Y, Oster S, et al. Axl and error-prone dna replication confer drug resistance and offer strategies to treat egfr-mutant lung cancer. Cancer Discov. 2022;12(11):2666\u201383.","journal-title":"Cancer Discov"},{"key":"2210_CR40","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12885-015-1916-3","volume":"15","author":"CD May","year":"2015","unstructured":"May CD, Garnett J, Ma X, Landers SM, Ingram DR, Demicco EG, et al. Axl is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer. 2015;15:901.","journal-title":"BMC Cancer"},{"issue":"12","key":"2210_CR41","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1007\/s11064-017-2399-1","volume":"42","author":"H Huang","year":"2017","unstructured":"Huang H, Liu H, Yan R, Hu M. Pi3k\/akt and erk\/mapk signaling promote different aspects of neuron survival and axonal regrowth following rat facial nerve axotomy. Neurochem Res. 2017;42(12):3515\u201324.","journal-title":"Neurochem Res"},{"issue":"3","key":"2210_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4161\/cbt.27541","volume":"15","author":"P Dent","year":"2014","unstructured":"Dent P. Crosstalk between erk, akt, and cell survival. Cancer Biol Ther. 2014;15(3):245\u20136.","journal-title":"Cancer Biol Ther"},{"issue":"14","key":"2210_CR43","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/onc.2010.555","volume":"30","author":"WB Ou","year":"2011","unstructured":"Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, et al. Axl regulates mesothelioma proliferation and invasiveness. Oncogene. 2011;30(14):1643\u201352.","journal-title":"Oncogene"},{"issue":"1","key":"2210_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jcp.20265","volume":"204","author":"PP Sainaghi","year":"2005","unstructured":"Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. Gas6 induces proliferation in prostate carcinoma cell lines expressing the axl receptor. J Cell Physiol. 2005;204(1):36\u201344.","journal-title":"J Cell Physiol"},{"issue":"11","key":"2210_CR45","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1136\/gutjnl-2021-325272","volume":"71","author":"G Bellomo","year":"2022","unstructured":"Bellomo G, Rainer C, Quaranta V, Astuti Y, Raymant M, Boyd E, et al. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via gas6\/axl signalling axis. Gut. 2022;71(11):2284\u201399.","journal-title":"Gut"},{"key":"2210_CR46","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ebiom.2018.09.006","volume":"36","author":"YY Li","year":"2018","unstructured":"Li YY, Tao YW, Gao S, Li P, Zheng JM, Zhang SE, et al. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine mir-34a-5p. EBioMedicine. 2018;36:209\u201320.","journal-title":"EBioMedicine"},{"issue":"12","key":"2210_CR47","doi-asserted-by":"publisher","first-page":"113604","DOI":"10.1016\/j.celrep.2023.113604","volume":"42","author":"MA Goyette","year":"2023","unstructured":"Goyette MA, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault MP, et al. The receptor tyrosine kinase axl is required at multiple steps of the metastatic cascade during her2-positive breast cancer progression. Cell Rep. 2023;42(12):113604.","journal-title":"Cell Rep"},{"issue":"20","key":"2210_CR48","doi-asserted-by":"publisher","first-page":"k2746","DOI":"10.1126\/sciadv.abk2746","volume":"8","author":"A Adam-Artigues","year":"2022","unstructured":"Adam-Artigues A, Arenas EJ, Martinez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, et al. Targeting her2-axl heterodimerization to overcome resistance to her2 blockade in breast cancer. Sci Adv. 2022;8(20):k2746.","journal-title":"Sci Adv"},{"issue":"28","key":"2210_CR49","doi-asserted-by":"publisher","first-page":"e2024596118","DOI":"10.1073\/pnas.2024596118","volume":"118","author":"D Zdzalik-Bielecka","year":"2021","unstructured":"Zdzalik-Bielecka D, Poswiata A, Kozik K, Jastrzebski K, Schink KO, Brewinska-Olchowik M, et al. The gas6-axl signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion. Proc Natl Acad Sci U S A. 2021;118(28):e2024596118.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"29","key":"2210_CR50","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1038\/onc.2008.57","volume":"27","author":"KY Tai","year":"2008","unstructured":"Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW. Axl promotes cell invasion by inducing mmp-9 activity through activation of nf-kappab and brg-1. Oncogene. 2008;27(29):4044\u201355.","journal-title":"Oncogene"},{"issue":"6","key":"2210_CR51","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jtho.2020.01.015","volume":"15","author":"ML Lotsberg","year":"2020","unstructured":"Lotsberg ML, Wnuk-Lipinska K, Terry S, Tan TZ, Lu N, Trachsel-Moncho L, et al. Axl targeting abrogates autophagic flux and induces immunogenic cell death in drug-resistant cancer cells. J Thorac Oncol. 2020;15(6):973\u201399.","journal-title":"J Thorac Oncol"},{"issue":"13","key":"2210_CR52","doi-asserted-by":"publisher","first-page":"869676","DOI":"10.3389\/fimmu.2022.869676","volume":"2022","author":"A Engelsen","year":"2022","unstructured":"Engelsen A, Lotsberg ML, Abou KR, Thiery JP, Lorens JB, Chouaib S, et al. Dissecting the role of axl in cancer immune escape and resistance to immune checkpoint inhibition. Front Immunol. 2022;2022(13):869676.","journal-title":"Front Immunol"},{"issue":"24","key":"2210_CR53","doi-asserted-by":"publisher","first-page":"6749","DOI":"10.1158\/1078-0432.CCR-21-0972","volume":"27","author":"S Terry","year":"2021","unstructured":"Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, et al. Association of axl and pd-l1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with pd-1 blockade. Clin Cancer Res. 2021;27(24):6749\u201360.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2210_CR54","doi-asserted-by":"publisher","first-page":"41064","DOI":"10.18632\/oncotarget.17026","volume":"8","author":"JZ Lin","year":"2017","unstructured":"Lin JZ, Wang ZJ, De W, Zheng M, Xu WZ, Wu HF, et al. Targeting axl overcomes resistance to docetaxel therapy in advanced prostate cancer. Oncotarget. 2017;8(25):41064\u201377.","journal-title":"Oncotarget"},{"issue":"7","key":"2210_CR55","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41401-020-00546-8","volume":"42","author":"M Tian","year":"2021","unstructured":"Tian M, Chen XS, Li LY, Wu HZ, Zeng D, Wang XL, et al. Inhibition of axl enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis. Acta Pharmacol Sin. 2021;42(7):1180\u20139.","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"2210_CR56","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cell.2018.03.052","volume":"173","author":"AC Bester","year":"2018","unstructured":"Bester AC, Lee JD, Chavez A, Lee YR, Nachmani D, Vora S, et al. An integrated genome-wide crispra approach to functionalize lncrnas in drug resistance. Cell. 2018;173(3):649\u201364.","journal-title":"Cell"},{"issue":"7","key":"2210_CR57","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.7150\/thno.91456","volume":"14","author":"N Vandewalle","year":"2024","unstructured":"Vandewalle N, Satilmis H, Verheye E, Fan R, Wang Y, De Groof T, et al. Axl-specific single domain antibodies show diagnostic potential and anti-tumor activity in acute myeloid leukemia. Theranostics. 2024;14(7):2656\u201374.","journal-title":"Theranostics"},{"issue":"2","key":"2210_CR58","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1158\/1541-7786.MCR-21-0302","volume":"20","author":"MM Mullen","year":"2022","unstructured":"Mullen MM, Lomonosova E, Toboni MD, Oplt A, Cybulla E, Blachut B, et al. Gas6\/axl inhibition enhances ovarian cancer sensitivity to chemotherapy and parp inhibition through increased dna damage and enhanced replication stress. Mol Cancer Res. 2022;20(2):265\u201379.","journal-title":"Mol Cancer Res"},{"issue":"39","key":"2210_CR59","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1038\/s41388-023-02810-7","volume":"42","author":"K Okamoto","year":"2023","unstructured":"Okamoto K, Ando T, Izumi H, Kobayashi SS, Shintani T, Gutkind JS, et al. Axl activates yap through the egfr-lats1\/2 axis and confers resistance to egfr-targeted drugs in head and neck squamous cell carcinoma. Oncogene. 2023;42(39):2869\u201377.","journal-title":"Oncogene"},{"issue":"4","key":"2210_CR60","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ccell.2015.03.010","volume":"27","author":"M Elkabets","year":"2015","unstructured":"Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, et al. Axl mediates resistance to pi3kalpha inhibition by activating the egfr\/pkc\/mtor axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell. 2015;27(4):533\u201346.","journal-title":"Cancer Cell"},{"issue":"2","key":"2210_CR61","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41419-024-06493-0","volume":"15","author":"Y Xie","year":"2024","unstructured":"Xie Y, Wu H, He Y, Liu L, Huang IB, Zhou L, et al. Targeting axl induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer. Cell Death Dis. 2024;15(2):110.","journal-title":"Cell Death Dis"},{"issue":"24","key":"2210_CR62","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.2021014241","volume":"140","author":"M Janssen","year":"2022","unstructured":"Janssen M, Schmidt C, Bruch PM, Blank MF, Rohde C, Waclawiczek A, et al. Venetoclax synergizes with gilteritinib in flt3 wild-type high-risk acute myeloid leukemia by suppressing mcl-1. Blood. 2022;140(24):2594\u2013610.","journal-title":"Blood"},{"issue":"26","key":"2210_CR63","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1182\/blood.2020007651","volume":"137","author":"X Niu","year":"2021","unstructured":"Niu X, Rothe K, Chen M, Grasedieck S, Li R, Nam SE, et al. Targeting axl kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia. Blood. 2021;137(26):3641\u201355.","journal-title":"Blood"},{"issue":"8","key":"2210_CR64","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/ng.2330","volume":"44","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the axl kinase causes resistance to egfr-targeted therapy in lung cancer. Nat Genet. 2012;44(8):852\u201360.","journal-title":"Nat Genet"},{"issue":"12","key":"2210_CR65","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1080\/15548627.2016.1235124","volume":"12","author":"J Han","year":"2016","unstructured":"Han J, Bae J, Choi CY, Choi SP, Kang HS, Jo EK, et al. Autophagy induced by axl receptor tyrosine kinase alleviates acute liver injury via inhibition of nlrp3 inflammasome activation in mice. Autophagy. 2016;12(12):2326\u201343.","journal-title":"Autophagy"},{"issue":"5","key":"2210_CR66","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/0008-5472.CAN-23-1459","volume":"84","author":"M Marquez-Palencia","year":"2024","unstructured":"Marquez-Palencia M, Reza HL, Parida PK, Ghosh S, Kim K, Das NM, et al. Axl\/wrnip1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in her2+ breast cancer. Cancer Res. 2024;84(5):675\u201387.","journal-title":"Cancer Res"},{"issue":"3","key":"2210_CR67","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s12072-023-10572-3","volume":"18","author":"T Tanaka","year":"2024","unstructured":"Tanaka T, Koga H, Suzuki H, Iwamoto H, Sakaue T, Masuda A, et al. Anti-pd-l1 antibodies promote cellular proliferation by activating the pd-l1-axl signal relay in liver cancer cells. Hepatol Int. 2024;18(3):984\u201397.","journal-title":"Hepatol Int"},{"issue":"1","key":"2210_CR68","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13073-020-00741-6","volume":"12","author":"HW Lee","year":"2020","unstructured":"Lee HW, Chung W, Lee HO, Jeong DE, Jo A, Lim JE, et al. Single-cell rna sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 2020;12(1):47.","journal-title":"Genome Med"},{"issue":"1","key":"2210_CR69","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41392-021-00745-7","volume":"6","author":"M Li","year":"2021","unstructured":"Li M, Hao B, Zhang M, Reiter RJ, Lin S, Zheng T, et al. Melatonin enhances radiofrequency-induced nk antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development. Signal Transduct Target Ther. 2021;6(1):330.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2210_CR70","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1073\/pnas.1812266115","volume":"116","author":"I Kaplanov","year":"2019","unstructured":"Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin GV, Shurin MR, et al. Blocking il-1beta reverses the immunosuppression in mouse breast cancer and synergizes with anti-pd-1 for tumor abrogation. Proc Natl Acad Sci U S A. 2019;116(4):1361\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2210_CR71","doi-asserted-by":"publisher","first-page":"103460","DOI":"10.1016\/j.ebiom.2021.103460","volume":"69","author":"Y Yu","year":"2021","unstructured":"Yu Y, He Z, Ouyang J, Tan Y, Chen Y, Gu Y, et al. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: a machine learning, multicenter study. EBioMedicine. 2021;69:103460.","journal-title":"EBioMedicine"},{"key":"2210_CR72","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03697-w","author":"Z Li","year":"2024","unstructured":"Li Z, Li J, Bai X, et al. Tumor microenvironment as a complex milieu driving cancer progression: a mini review. Clin Transl Oncol. 2024. https:\/\/doi.org\/10.1007\/s12094-024-03697-w.","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"2210_CR73","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.ccell.2022.11.005","volume":"40","author":"Z Ma","year":"2022","unstructured":"Ma Z, Li X, Mao Y, Wei C, Huang Z, Li G, et al. Interferon-dependent slc14a1(+) cancer-associated fibroblasts promote cancer stemness via wnt5a in bladder cancer. Cancer Cell. 2022;40(12):1550\u201365.","journal-title":"Cancer Cell"},{"issue":"1","key":"2210_CR74","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13046-023-02934-4","volume":"42","author":"R Melchionna","year":"2023","unstructured":"Melchionna R, Trono P, Di Carlo A, Di Modugno F, Nistico P. Transcription factors in fibroblast plasticity and caf heterogeneity. J Exp Clin Cancer Res. 2023;42(1):347.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2210_CR75","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12943-023-01737-7","volume":"22","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Cheng L, Liu L, Li X. Nk cells are never alone: crosstalk and communication in tumour microenvironments. Mol Cancer. 2023;22(1):34.","journal-title":"Mol Cancer"},{"issue":"5795","key":"2210_CR76","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960\u20134.","journal-title":"Science"},{"key":"2210_CR77","doi-asserted-by":"publisher","first-page":"216894","DOI":"10.1016\/j.canlet.2024.216894","volume":"591","author":"M El-Tanani","year":"2024","unstructured":"El-Tanani M, Rabbani SA, Babiker R, Rangraze I, Kapre S, Palakurthi SS, et al. Unraveling the tumor microenvironment: insights into cancer metastasis and therapeutic strategies. Cancer Lett. 2024;591:216894.","journal-title":"Cancer Lett"},{"issue":"4","key":"2210_CR78","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun AM, Thommen DS, Schumacher TN. Cd8(+) t cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218\u201332.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2210_CR79","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12943-019-1022-2","volume":"18","author":"KV Myers","year":"2019","unstructured":"Myers KV, Amend SR, Pienta KJ. Targeting tyro3, axl and mertk (tam receptors): implications for macrophages in the tumor microenvironment. Mol Cancer. 2019;18(1):94.","journal-title":"Mol Cancer"},{"issue":"9","key":"2210_CR80","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.4049\/jimmunol.178.9.5635","volume":"178","author":"HM Seitz","year":"2007","unstructured":"Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK. Macrophages and dendritic cells use different axl\/mertk\/tyro3 receptors in clearance of apoptotic cells. J Immunol. 2007;178(9):5635\u201342.","journal-title":"J Immunol"},{"key":"2210_CR81","doi-asserted-by":"publisher","first-page":"6848430","DOI":"10.1155\/2017\/6848430","volume":"2017","author":"GJ Zhao","year":"2017","unstructured":"Zhao GJ, Zheng JY, Bian JL, Chen LW, Dong N, Yu Y, et al. Growth arrest-specific 6 enhances the suppressive function of cd4(+)cd25(+) regulatory t cells mainly through axl receptor. Mediators Inflamm. 2017;2017:6848430.","journal-title":"Mediators Inflamm"},{"issue":"8","key":"2210_CR82","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s41591-018-0116-5","volume":"24","author":"I Canadas","year":"2018","unstructured":"Canadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018;24(8):1143\u201350.","journal-title":"Nat Med"},{"key":"2210_CR83","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","volume":"15","author":"M Locati","year":"2020","unstructured":"Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123\u201347.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"2210_CR84","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14\u201320.","journal-title":"Immunity"},{"issue":"4","key":"2210_CR85","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/ijc.25113","volume":"127","author":"M van Dongen","year":"2010","unstructured":"van Dongen M, Savage ND, Jordanova ES, Briaire-de BI, Walburg KV, Ottenhoff TH, et al. Anti-inflammatory m2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer. 2010;127(4):899\u2013909.","journal-title":"Int J Cancer"},{"issue":"13","key":"2210_CR86","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1158\/1078-0432.CCR-09-0489","volume":"15","author":"AP Lepique","year":"2009","unstructured":"Lepique AP, Daghastanli KR, Cuccovia IM, Villa LL. Hpv16 tumor associated macrophages suppress antitumor t cell responses. Clin Cancer Res. 2009;15(13):4391\u2013400.","journal-title":"Clin Cancer Res"},{"key":"2210_CR87","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.intimp.2016.01.023","volume":"34","author":"Q Han","year":"2016","unstructured":"Han Q, Shi H, Liu F. Cd163(+) m2-type tumor-associated macrophage support the suppression of tumor-infiltrating t cells in osteosarcoma. Int Immunopharmacol. 2016;34:101\u20136.","journal-title":"Int Immunopharmacol"},{"issue":"46","key":"2210_CR88","doi-asserted-by":"publisher","first-page":"75339","DOI":"10.18632\/oncotarget.12180","volume":"7","author":"F Finkernagel","year":"2016","unstructured":"Finkernagel F, Reinartz S, Lieber S, Adhikary T, Wortmann A, Hoffmann N, et al. The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. Oncotarget. 2016;7(46):75339\u201352.","journal-title":"Oncotarget"},{"issue":"7598","key":"2210_CR89","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature17630","volume":"532","author":"L Fourgeaud","year":"2016","unstructured":"Fourgeaud L, Traves PG, Tufail Y, Leal-Bailey H, Lew ED, Burrola PG, et al. Tam receptors regulate multiple features of microglial physiology. Nature. 2016;532(7598):240\u20134.","journal-title":"Nature"},{"issue":"5","key":"2210_CR90","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/eji.201747283","volume":"48","author":"AM Grabiec","year":"2018","unstructured":"Grabiec AM, Goenka A, Fife ME, Fujimori T, Hussell T. Axl and mertk receptor tyrosine kinases maintain human macrophage efferocytic capacity in the presence of viral triggers. Eur J Immunol. 2018;48(5):855\u201360.","journal-title":"Eur J Immunol"},{"issue":"8","key":"2210_CR91","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.4049\/jimmunol.1302766","volume":"192","author":"T Shibata","year":"2014","unstructured":"Shibata T, Habiel DM, Coelho AL, Kunkel SL, Lukacs NW, Hogaboam CM. Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma. J Immunol. 2014;192(8):3569\u201381.","journal-title":"J Immunol"},{"issue":"9","key":"2210_CR92","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1158\/2326-6066.CIR-22-0254","volume":"11","author":"RL Sakemura","year":"2023","unstructured":"Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, et al. Axl inhibition improves the antitumor activity of chimeric antigen receptor t cells. Cancer Immunol Res. 2023;11(9):1222\u201336.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2210_CR93","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41401-022-01047-6","volume":"44","author":"JP Pei","year":"2023","unstructured":"Pei JP, Wang Y, Ma LP, Wang X, Liu L, Zhang Y, et al. Axl antibody and axl-adc mediate antitumor efficacy via targeting axl in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated m2-like macrophage. Acta Pharmacol Sin. 2023;44(6):1290\u2013303.","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"2210_CR94","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/rheumatology\/key337","volume":"58","author":"C Waterborg","year":"2019","unstructured":"Waterborg C, Broeren M, Blaney DE, Koenders MI, van Lent P, van den Berg WB, et al. The level of synovial axl expression determines the outcome of inflammatory arthritis, possibly depending on the upstream role of tgf-beta1. Rheumatology (Oxford). 2019;58(3):536\u201346.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2210_CR95","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1038\/s41467-024-46735-5","volume":"15","author":"M Cheng","year":"2024","unstructured":"Cheng M, Chen S, Li K, Wang G, Xiong G, Ling R, et al. Cd276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer. Nat Commun. 2024;15(1):2818.","journal-title":"Nat Commun"},{"issue":"11","key":"2210_CR96","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41590-023-01642-7","volume":"24","author":"SE Di Carlo","year":"2023","unstructured":"Di Carlo SE, Raffenne J, Varet H, Ode A, Granados DC, Stein M, et al. Depletion of slow-cycling pdgfralpha(+)adam12(+) mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis. Nat Immunol. 2023;24(11):1867\u201378.","journal-title":"Nat Immunol"},{"issue":"7","key":"2210_CR97","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.oraloncology.2015.04.004","volume":"51","author":"KC Chiu","year":"2015","unstructured":"Chiu KC, Lee CH, Liu SY, Chou YT, Huang RY, Huang SM, et al. Polarization of tumor-associated macrophages and gas6\/axl signaling in oral squamous cell carcinoma. Oral Oncol. 2015;51(7):683\u20139.","journal-title":"Oral Oncol"},{"issue":"10","key":"2210_CR98","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.joen.2018.07.005","volume":"44","author":"HW Yeh","year":"2018","unstructured":"Yeh HW, Chiang CF, Chen PH, Su CC, Wu YC, Chou L, et al. Axl involved in mineral trioxide aggregate induces macrophage polarization. J Endod. 2018;44(10):1542\u20138.","journal-title":"J Endod"},{"key":"2210_CR99","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.etap.2016.05.029","volume":"45","author":"Y Shen","year":"2016","unstructured":"Shen Y, Cui X, Rong Y, Zhang Z, Xiao L, Zhou T, et al. Exogenous gas6 attenuates silica-induced inflammation on differentiated thp-1 macrophages. Environ Toxicol Pharmacol. 2016;45:222\u20136.","journal-title":"Environ Toxicol Pharmacol"},{"issue":"1","key":"2210_CR100","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1365-2567.2011.03511.x","volume":"135","author":"T Deng","year":"2012","unstructured":"Deng T, Zhang Y, Chen Q, Yan K, Han D. Toll-like receptor-mediated inhibition of gas6 and pros expression facilitates inflammatory cytokine production in mouse macrophages. Immunology. 2012;135(1):40\u201350.","journal-title":"Immunology"},{"issue":"1","key":"2210_CR101","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s42003-022-04401-w","volume":"5","author":"TS Rigoni","year":"2022","unstructured":"Rigoni TS, Vellozo NS, Guimaraes-Pinto K, Cabral-Piccin M, Fabiano-Coelho L, Matos-Silva TC, et al. Axl receptor induces efferocytosis, dampens m1 macrophage responses and promotes heart pathology in trypanosoma cruzi infection. Commun Biol. 2022;5(1):1421.","journal-title":"Commun Biol"},{"key":"2210_CR102","doi-asserted-by":"publisher","first-page":"1158758","DOI":"10.3389\/fimmu.2023.1158758","volume":"14","author":"Y Han","year":"2023","unstructured":"Han Y, Li G, Zhang Z, Zhang X, Zhao B, Yang H. Axl promotes intracranial aneurysm rupture by regulating macrophage polarization toward m1 via stat1\/hif-1alpha. Front Immunol. 2023;14:1158758.","journal-title":"Front Immunol"},{"issue":"5","key":"2210_CR103","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/hed.27340","volume":"45","author":"KL Kostecki","year":"2023","unstructured":"Kostecki KL, Iida M, Wiley AL, Kimani S, Mehall B, Tetreault K, et al. Dual axl\/mertk inhibitor incb081776 creates a proinflammatory tumor immune microenvironment and enhances anti-pdl1 efficacy in head and neck cancer. Head Neck. 2023;45(5):1255\u201371.","journal-title":"Head Neck"},{"issue":"9","key":"2210_CR104","doi-asserted-by":"publisher","first-page":"113067","DOI":"10.1016\/j.celrep.2023.113067","volume":"42","author":"CN Hung","year":"2023","unstructured":"Hung CN, Chen M, DeArmond DT, Chiu CH, Limboy CA, Tan X, et al. Axl-initiated paracrine activation of pstat3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages. Cell Rep. 2023;42(9):113067.","journal-title":"Cell Rep"},{"issue":"19\u201320","key":"2210_CR105","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1101\/gad.340661.120","volume":"34","author":"B King","year":"2020","unstructured":"King B, Araki J, Palm W, Thompson CB. Yap\/taz promote the scavenging of extracellular nutrients through macropinocytosis. Genes Dev. 2020;34(19\u201320):1345\u201358.","journal-title":"Genes Dev"},{"issue":"7","key":"2210_CR106","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.cell.2011.12.006","volume":"147","author":"CZ Han","year":"2011","unstructured":"Han CZ, Ravichandran KS. Metabolic connections during apoptotic cell engulfment. Cell. 2011;147(7):1442\u20135.","journal-title":"Cell"},{"issue":"9","key":"2210_CR107","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.tem.2013.04.004","volume":"24","author":"T Roszer","year":"2013","unstructured":"Roszer T, Menendez-Gutierrez MP, Cedenilla M, Ricote M. Retinoid x receptors in macrophage biology. Trends Endocrinol Metab. 2013;24(9):460\u20138.","journal-title":"Trends Endocrinol Metab"},{"key":"2210_CR108","doi-asserted-by":"publisher","first-page":"13130","DOI":"10.1038\/ncomms13130","volume":"7","author":"T Kimura","year":"2016","unstructured":"Kimura T, Nada S, Takegahara N, Okuno T, Nojima S, Kang S, et al. Polarization of m2 macrophages requires lamtor1 that integrates cytokine and amino-acid signals. Nat Commun. 2016;7:13130.","journal-title":"Nat Commun"},{"issue":"6","key":"2210_CR109","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1210\/me.2007-0525","volume":"22","author":"A Gallardo-Soler","year":"2008","unstructured":"Gallardo-Soler A, Gomez-Nieto C, Campo ML, Marathe C, Tontonoz P, Castrillo A, et al. Arginase i induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-gamma\/delta-mediated effect that links lipid metabolism and immunity. Mol Endocrinol. 2008;22(6):1394\u2013402.","journal-title":"Mol Endocrinol"},{"issue":"7148","key":"2210_CR110","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature05894","volume":"447","author":"JI Odegaard","year":"2007","unstructured":"Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, et al. Macrophage-specific ppargamma controls alternative activation and improves insulin resistance. Nature. 2007;447(7148):1116\u201320.","journal-title":"Nature"},{"issue":"2","key":"2210_CR111","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.cmet.2007.06.010","volume":"6","author":"MA Bouhlel","year":"2007","unstructured":"Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, et al. Ppargamma activation primes human monocytes into alternative m2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6(2):137\u201343.","journal-title":"Cell Metab"},{"issue":"5","key":"2210_CR112","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.bbadis.2014.12.019","volume":"1852","author":"F Penas","year":"2015","unstructured":"Penas F, Mirkin GA, Vera M, Cevey A, Gonzalez CD, Gomez MI, et al. Treatment in vitro with pparalpha and ppargamma ligands drives m1-to-m2 polarization of macrophages from t. Cruzi-infected mice Biochim Biophys Acta. 2015;1852(5):893\u2013904.","journal-title":"Cruzi-infected mice Biochim Biophys Acta"},{"issue":"2","key":"2210_CR113","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1158\/1535-7163.MCT-22-0262","volume":"22","author":"J Hsu","year":"2023","unstructured":"Hsu J, Chong C, Serrill J, Goon L, Balayan J, Johnson EN, et al. Preclinical characterization of xl092, a novel receptor tyrosine kinase inhibitor of met, vegfr2, axl, and mer. Mol Cancer Ther. 2023;22(2):179\u201391.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2210_CR114","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2210_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310.","journal-title":"Immunity"},{"issue":"7378","key":"2210_CR116","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480\u20139.","journal-title":"Nature"},{"issue":"6024","key":"2210_CR117","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331(6024):1565\u201370.","journal-title":"Science"},{"key":"2210_CR118","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev.immunol.24.021605.090733","volume":"24","author":"T Boon","year":"2006","unstructured":"Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human t cell responses against melanoma. Annu Rev Immunol. 2006;24:175\u2013208.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"2210_CR119","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547\u201362.","journal-title":"Cancer Cell"},{"issue":"6","key":"2210_CR120","doi-asserted-by":"publisher","first-page":"e1303","DOI":"10.1002\/ctm2.1303","volume":"13","author":"C Wu","year":"2023","unstructured":"Wu C, Duan L, Li H, Liu X, Cai T, Yang Y, et al. Pd1(hi) cd200(hi) cd4(+) exhausted t cell increase immunotherapy resistance and tumour progression by promoting epithelial-mesenchymal transition in bladder cancer. Clin Transl Med. 2023;13(6):e1303.","journal-title":"Clin Transl Med"},{"key":"2210_CR121","doi-asserted-by":"crossref","unstructured":"Pizzimenti C, Fiorentino V, Ieni A, Rossi ED, Germana E, Giovanella L, et al. Braf-axl-pd-l1 signaling axis as a possible biological marker for rai treatment in the thyroid cancer ata intermediate risk category. Int J Mol Sci. 2023 12;24(12):10024.","DOI":"10.3390\/ijms241210024"},{"issue":"11","key":"2210_CR122","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1158\/1078-0432.CCR-16-2586","volume":"23","author":"HD Skinner","year":"2017","unstructured":"Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, et al. Integrative analysis identifies a novel axl-pi3 kinase-pd-l1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res. 2017;23(11):2713\u201322.","journal-title":"Clin Cancer Res"},{"issue":"7802","key":"2210_CR123","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020;580(7802):257\u201362.","journal-title":"Nature"},{"issue":"1","key":"2210_CR124","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12943-019-0953-y","volume":"18","author":"Y Tsukita","year":"2019","unstructured":"Tsukita Y, Fujino N, Miyauchi E, Saito R, Fujishima F, Itakura K, et al. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas. Mol Cancer. 2019;18(1):24.","journal-title":"Mol Cancer"},{"key":"2210_CR125","doi-asserted-by":"publisher","first-page":"13898","DOI":"10.1038\/ncomms13898","volume":"7","author":"TA Aguilera","year":"2016","unstructured":"Aguilera TA, Rafat M, Castellini L, Shehade H, Kariolis MS, Hui AB, et al. Reprogramming the immunological microenvironment through radiation and targeting axl. Nat Commun. 2016;7:13898.","journal-title":"Nat Commun"},{"issue":"11","key":"2210_CR126","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/2326-6066.CIR-18-0903","volume":"7","author":"S Terry","year":"2019","unstructured":"Terry S, Abdou A, Engelsen A, Buart S, Dessen P, Corgnac S, et al. Axl targeting overcomes human lung cancer cell resistance to nk- and ctl-mediated cytotoxicity. Cancer Immunol Res. 2019;7(11):1789\u2013802.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"2210_CR127","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.xcrm.2022.100554","volume":"3","author":"H Li","year":"2022","unstructured":"Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, et al. Axl targeting restores pd-1 blockade sensitivity of stk11\/lkb1 mutant nsclc through expansion of tcf1(+) cd8 t cells. Cell Rep Med. 2022;3(3):100554.","journal-title":"Cell Rep Med"},{"issue":"1","key":"2210_CR128","doi-asserted-by":"publisher","first-page":"6203","DOI":"10.1038\/s41467-022-33968-5","volume":"13","author":"B Cao","year":"2022","unstructured":"Cao B, Liu M, Wang L, Zhu K, Cai M, Chen X, et al. Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of axl-specific car t cells against non-small cell lung cancer. Nat Commun. 2022;13(1):6203.","journal-title":"Nat Commun"},{"issue":"2","key":"2210_CR129","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ijc.2910160205","volume":"16","author":"RB Herberman","year":"1975","unstructured":"Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors .Ii. Characterization of effector cells. Int J Cancer. 1975;16(2):230\u20139.","journal-title":"Int J Cancer."},{"key":"2210_CR130","doi-asserted-by":"crossref","unstructured":"Kiessling R, Klein E, Wigzell H. \"natural\" killer cells in the mouse .I. Cytotoxic cells with specificity for mouse moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5(2):112\u201317.","DOI":"10.1002\/eji.1830050208"},{"issue":"3","key":"2210_CR131","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1046\/j.1365-3083.2002.01053.x","volume":"55","author":"K Karre","year":"2002","unstructured":"Karre K. Nk cells, mhc class i molecules and the missing self. Scand J Immunol. 2002;55(3):221\u20138.","journal-title":"Scand J Immunol"},{"key":"2210_CR132","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847.","journal-title":"Front Immunol"},{"issue":"2","key":"2210_CR133","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jri.2010.11.002","volume":"88","author":"SM Blois","year":"2011","unstructured":"Blois SM, Klapp BF, Barrientos G. Decidualization and angiogenesis in early pregnancy: unravelling the functions of dc and nk cells. J Reprod Immunol. 2011;88(2):86\u201392.","journal-title":"J Reprod Immunol"},{"issue":"9","key":"2210_CR134","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm1452","volume":"12","author":"J Hanna","year":"2006","unstructured":"Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, et al. Decidual nk cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006;12(9):1065\u201374.","journal-title":"Nat Med"},{"issue":"26","key":"2210_CR135","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.18632\/oncotarget.27654","volume":"11","author":"Y Guan","year":"2020","unstructured":"Guan Y, Chambers CB, Tabatabai T, Hatley H, Delfino KR, Robinson K, et al. Renal cell tumors convert natural killer cells to a proangiogenic phenotype. Oncotarget. 2020;11(26):2571\u201385.","journal-title":"Oncotarget"},{"issue":"2","key":"2210_CR136","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1593\/neo.121758","volume":"15","author":"A Bruno","year":"2013","unstructured":"Bruno A, Focaccetti C, Pagani A, Imperatori AS, Spagnoletti M, Rotolo N, et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia. 2013;15(2):133\u201342.","journal-title":"Neoplasia"},{"issue":"15","key":"2210_CR137","doi-asserted-by":"publisher","first-page":"13835","DOI":"10.18632\/oncotarget.3453","volume":"6","author":"I Levi","year":"2015","unstructured":"Levi I, Amsalem H, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O, et al. Characterization of tumor infiltrating natural killer cell subset. Oncotarget. 2015;6(15):13835\u201343.","journal-title":"Oncotarget"},{"issue":"9","key":"2210_CR138","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1172\/JCI45816","volume":"121","author":"E Mamessier","year":"2011","unstructured":"Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from nk cell antitumor immunity. J Clin Invest. 2011;121(9):3609\u201322.","journal-title":"J Clin Invest"},{"issue":"10","key":"2210_CR139","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1096\/fj.201701103R","volume":"32","author":"A Bruno","year":"2018","unstructured":"Bruno A, Bassani B, D\u2019Urso DG, Pitaku I, Cassinotti E, Pelosi G, et al. Angiogenin and the mmp9-timp2 axis are up-regulated in proangiogenic, decidual nk-like cells from patients with colorectal cancer. Faseb J. 2018;32(10):5365\u201377.","journal-title":"Faseb J"},{"issue":"1","key":"2210_CR140","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/1753425912453187","volume":"19","author":"YS Rocca","year":"2013","unstructured":"Rocca YS, Roberti MP, Arriaga JM, Amat M, Bruno L, Pampena MB, et al. Altered phenotype in peripheral blood and tumor-associated nk cells from colorectal cancer patients. Innate Immun. 2013;19(1):76\u201385.","journal-title":"Innate Immun"},{"issue":"13","key":"2210_CR141","doi-asserted-by":"publisher","first-page":"888313","DOI":"10.3389\/fimmu.2022.888313","volume":"2022","author":"D Corvino","year":"2022","unstructured":"Corvino D, Kumar A, Bald T. Plasticity of nk cells in cancer. Front Immunol. 2022;2022(13):888313.","journal-title":"Front Immunol"},{"issue":"4","key":"2210_CR142","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massague J. Transforming growth factor-beta signaling in immunity and cancer. Immunity. 2019;50(4):924\u201340.","journal-title":"Immunity"},{"issue":"415","key":"2210_CR143","doi-asserted-by":"publisher","first-page":"a19","DOI":"10.1126\/scisignal.aad1884","volume":"9","author":"S Viel","year":"2016","unstructured":"Viel S, Marcais A, Guimaraes FS, Loftus R, Rabilloud J, Grau M, et al. Tgf-beta inhibits the activation and functions of nk cells by repressing the mtor pathway. Sci Signal. 2016;9(415):a19.","journal-title":"Sci Signal"},{"issue":"12","key":"2210_CR144","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.4049\/jimmunol.1701461","volume":"200","author":"V Zaiatz-Bittencourt","year":"2018","unstructured":"Zaiatz-Bittencourt V, Finlay DK, Gardiner CM. Canonical tgf-beta signaling pathway represses human nk cell metabolism. J Immunol. 2018;200(12):3934\u201341.","journal-title":"J Immunol"},{"issue":"11","key":"2210_CR145","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1182\/blood-2008-05-157073","volume":"113","author":"IK Park","year":"2009","unstructured":"Park IK, Giovenzana C, Hughes TL, Yu J, Trotta R, Caligiuri MA. The axl\/gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. Blood. 2009;113(11):2470\u20137.","journal-title":"Blood"},{"issue":"2","key":"2210_CR146","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00709-016-1016-5","volume":"254","author":"EM Kim","year":"2017","unstructured":"Kim EM, Lee EH, Lee HY, Choi HR, Ji KY, Kim SM, et al. Axl signaling induces development of natural killer cells in vitro and in vivo. Protoplasma. 2017;254(2):1091\u2013101.","journal-title":"Protoplasma"},{"issue":"7493","key":"2210_CR147","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature12998","volume":"507","author":"M Paolino","year":"2014","unstructured":"Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, et al. The e3 ligase cbl-b and tam receptors regulate cancer metastasis via natural killer cells. Nature. 2014;507(7493):508\u201312.","journal-title":"Nature"},{"issue":"1","key":"2210_CR148","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/eji.201948204","volume":"50","author":"LM Chirino","year":"2020","unstructured":"Chirino LM, Kumar S, Okumura M, Sterner DE, Mattern M, Butt TR, et al. Tam receptors attenuate murine nk-cell responses via e3 ubiquitin ligase cbl-b. Eur J Immunol. 2020;50(1):48\u201355.","journal-title":"Eur J Immunol"},{"issue":"6282","key":"2210_CR149","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MN, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell rna-seq. Science. 2016;352(6282):189\u201396.","journal-title":"Science"},{"key":"2210_CR150","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD. Improving car-t immunotherapy: overcoming the challenges of t cell exhaustion. EBioMedicine. 2022;77:103941.","journal-title":"EBioMedicine"},{"issue":"10","key":"2210_CR151","doi-asserted-by":"publisher","first-page":"e20230053","DOI":"10.1084\/jem.20230053","volume":"220","author":"K DePeaux","year":"2023","unstructured":"DePeaux K, Rivadeneira DB, Lontos K, Dean VG, Gunn WG, Watson MJ, et al. An oncolytic virus-delivered tgfbeta inhibitor overcomes the immunosuppressive tumor microenvironment. J Exp Med. 2023;220(10):e20230053.","journal-title":"J Exp Med."},{"issue":"7","key":"2210_CR152","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.molmed.2024.04.008","volume":"30","author":"A Arthur","year":"2024","unstructured":"Arthur A, Nejmi S, Franchini DM, Espinos E, Millevoi S. Pd-l1 at the crossroad between rna metabolism and immunosuppression. Trends Mol Med. 2024;30(7):620\u201332.","journal-title":"Trends Mol Med"},{"issue":"7718","key":"2210_CR153","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal pd-l1 contributes to immunosuppression and is associated with anti-pd-1 response. Nature. 2018;560(7718):382\u20136.","journal-title":"Nature"},{"issue":"9","key":"2210_CR154","doi-asserted-by":"publisher","first-page":"e85974","DOI":"10.1172\/jci.insight.85974","volume":"1","author":"T Courau","year":"2016","unstructured":"Courau T, Nehar-Belaid D, Florez L, Levacher B, Vazquez T, Brimaud F, et al. Tgf-beta and vegf cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight. 2016;1(9):e85974.","journal-title":"JCI Insight"},{"issue":"1","key":"2210_CR155","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1038\/s41467-022-31141-6","volume":"13","author":"Y Shen","year":"2022","unstructured":"Shen Y, Lu C, Song Z, Qiao C, Wang J, Chen J, et al. Ursodeoxycholic acid reduces antitumor immunosuppression by inducing chip-mediated tgf-beta degradation. Nat Commun. 2022;13(1):3419.","journal-title":"Nat Commun"},{"issue":"1","key":"2210_CR156","doi-asserted-by":"publisher","first-page":"2300846","DOI":"10.1080\/19490976.2023.2300846","volume":"16","author":"SY Lee","year":"2024","unstructured":"Lee SY, Jhun J, Woo JS, Lee KH, Hwang SH, Moon J, et al. Gut microbiome-derived butyrate inhibits the immunosuppressive factors pd-l1 and il-10 in tumor-associated macrophages in gastric cancer. Gut Microbes. 2024;16(1):2300846.","journal-title":"Gut Microbes"},{"key":"2210_CR157","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.coi.2014.12.009","volume":"34","author":"SK Mittal","year":"2015","unstructured":"Mittal SK, Roche PA. Suppression of antigen presentation by il-10. Curr Opin Immunol. 2015;34:22\u20137.","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"2210_CR158","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","volume":"37","author":"DH Munn","year":"2016","unstructured":"Munn DH, Mellor AL. Ido in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 2016;37(3):193\u2013207.","journal-title":"Trends Immunol"},{"issue":"1","key":"2210_CR159","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, et al. Blockade of the ahr restricts a treg-macrophage suppressive axis induced by l-kynurenine. Nat Commun. 2020;11(1):4011.","journal-title":"Nat Commun"},{"issue":"6","key":"2210_CR160","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00262-023-03370-1","volume":"72","author":"K Morimoto","year":"2023","unstructured":"Morimoto K, Yamada T, Sawada R, Azuma K, Goto Y, Harada T, et al. Predictive value of p53 and axl immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer. Cancer Immunol Immunother. 2023;72(6):1699\u2013707.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2210_CR161","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/s41591-024-03086-4","volume":"30","author":"H Ebrahimi","year":"2024","unstructured":"Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, et al. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2024;30(9):2576\u201385.","journal-title":"Nat Med."},{"issue":"19","key":"2210_CR162","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814\u201323.","journal-title":"N Engl J Med"},{"issue":"5","key":"2210_CR163","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","volume":"24","author":"TK Choueiri","year":"2023","unstructured":"Choueiri TK, McDermott DF, Merchan J, Bauer TM, Figlin R, Heath EI, et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. 2023;24(5):553\u201362.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2210_CR164","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (meteor): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917\u201327.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2210_CR165","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41401-024-01237-4","volume":"45","author":"R Han","year":"2024","unstructured":"Han R, Lu CH, Hu C, Dou YY, Kang J, Lin CY, et al. Brigatinib, a newly discovered axl inhibitor, suppresses axl-mediated acquired resistance to osimertinib in egfr-mutated non-small cell lung cancer. Acta Pharmacol Sin. 2024;45(6):1264\u201375.","journal-title":"Acta Pharmacol Sin."},{"issue":"12","key":"2210_CR166","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","volume":"30","author":"D Moro-Sibilot","year":"2019","unstructured":"Moro-Sibilot D, Cozic N, Perol M, Mazieres J, Otto J, Souquet PJ, et al. Crizotinib in c-met- or ros1-positive nsclc: results of the acse phase ii trial. Ann Oncol. 2019;30(12):1985\u201391.","journal-title":"Ann Oncol"},{"issue":"38","key":"2210_CR167","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1038\/onc.2010.268","volume":"29","author":"X Ye","year":"2010","unstructured":"Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, et al. An anti-axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene. 2010;29(38):5254\u201364.","journal-title":"Oncogene"},{"issue":"47","key":"2210_CR168","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1038\/onc.2013.487","volume":"33","author":"W Leconet","year":"2014","unstructured":"Leconet W, Larbouret C, Chardes T, Thomas G, Neiveyans M, Busson M, et al. Preclinical validation of axl receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene. 2014;33(47):5405\u201314.","journal-title":"Oncogene"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-02210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-024-02210-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-02210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T10:02:26Z","timestamp":1736589746000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-024-02210-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":168,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2210"],"URL":"https:\/\/doi.org\/10.1186\/s12943-024-02210-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}